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Left ventricular hypertrophy (LVH) is an abnormal 
increase in left ventricular mass. which is a marker for 
and contributes to coronary events, stroke, heart failure, 
peripheral arterial disease, and cardiovascular mortality 
in patients with hypertension (1-12). LVH is commonly 
measured by electrocardiography, echocardiography, 
and magnetic resonance imaging Concentric LVH is 
an increased left ventricular mass index with a relative 
wall thickness ≥0.45 (1). Eccentric LVH is an increased 
left ventricular mass index with a relative wall thickness 
<0.45 (1). Concentric left ventricular remodeling is a 
relative wall thickness ≥0.45 with a normal left ventricular 
mass index. Factors influencing left ventricular geometry 
in persons with hypertension include: (I) the severity, 
duration, and rapidity of onset of the increased pressure 
load; (II) the volume load; (III) age, race/ethnicity, and 
sex; (IV) comorbidities such as coronary artery disease, 
diabetes mellitus, obesity, and valvular heart disease; 
(V) the neurohormonal milieu; (VI) alterations of the 
extracellular matrix; and (VII) genetic factors (13). Blacks 
with hypertension are more likely than whites with 
hypertension to develop concentric LVH (13). Women with 
hypertension are more likely than men with hypertension 
to develop concentric LVH (13). Increasing age in patients 
with hypertension is associated with concentric LVH (13). 
Diabetes mellitus in patients with hypertension is associated 
with concentric LVH, whereas obesity, which is a volume 
overload state, and coronary artery disease in patients with 
hypertension are more likely to be associated with eccentric 
LVH (13).
The electrocardiogram is less sensitive than the 
echocardiogram or magnetic resonance imaging in 
diagnosing LVH. In a blinded prospective study of 476 
patients aged 62 years and older, echocardiographic LVH 
was 67% to 71% present in 167 patients (35%) (14). The 
sensitivity of 5 different electrocardiographic criteria in 
diagnosing LVH varied from 12% to 29%, the specificity 
from 93% to 96%, the positive predictive value from 62% 
to 71%, and the negative predictive value from 67% to 
71% (14). The Cornell criteria (15) had the highest 
sensitivity (29%) in predicting LVH, a specificity of 93%, a 
positive predictive value of 69%, and a negative predictive 
value of 71% (14).
In a prospective study of 84 blacks and 326 whites older 
than 62 years with hypertension, echocardiographic LVH 
was present in 71% of blacks and in 56% of whites (1). 
Electrocardiographic LVH was present in 20% of blacks 
and in 15% of whites (1). Concentric LVH was present 
in 60% of blacks and in 40% of whites (1). Eccentric 
LVH was present in 12% of blacks and in 17% of 
w h i t e s  ( 1 ) .  A t  3 7 - m o n t h  f o l l o w - u p  o f  b l a c k s , 
echocardiographic LVH increased the incidence of new 
coronary events 3.33 times, new stroke 2.76 times, and 
new congestive heart failure 3.69 times (1). At 43-month 
follow-up of whites, echocardiographic LVH increased 
the incidence of new coronary events 2.72 times, new 
stroke 2.76 times, and new congestive heart failure 
3.69 times (1).  At 37-month follow-up of blacks, 
electrocardiographic LVH increased the incidence of new 
coronary events 1.49 times, new stroke 1.79 times, and 
new congestive heart failure 1.31 times (1). At 43-month 
follow-up of whites, electrocardiographic LVH increased 
the incidence of new coronary events 1.41 times, new stroke 
1.94 times, and new congestive heart failure 1.58 times (1). 
In elderly blacks, compared with eccentric LVH, concentric 
LVH increased the incidence of new coronary events 
1.48 times, new stroke 1.2 times, and new congestive heart 
failure 1.73 times (1). In elderly whites, compared with 
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eccentric LVH, concentric LVH increased the incidence 
of new coronary events 1.42 times, new congestive heart 
failure 1.82 times, and had a similar incidence of new 
stroke (1). Echocardiographic LVH (odds ratio 3.21) 
and concentric LVH (odds ratio =2.63) were significant 
independent variables for new coronary events in the final 
multiple logistic regression model for all patients with 
hypertension (1). Echocardiographic LVH (odds ratio 4.17) 
and electrocardiographic LVH (odds ratio =2.10) were 
significant independent variables for new stroke in the 
final multiple logistic regression model for all patients with 
hypertension (1). Echocardiographic LVH (odds ratio 2.57) 
and concentric LVH (odds ratio =2.44) were significant 
independent variables for new coronary events in the final 
multiple logistic regression model for all patients with 
hypertension (1).
At 4-year follow-up of 406 men, mean age 68 years, 
and 735 women, mean age 69 years, in the Framingham 
Heart Study, echocardiographic LVH increased the risk of 
new coronary events 1.67 times for men and 1.60 times for 
women per 50 grams/meter increase in left ventricular mass/
height (3). Echocardiographic LVH was 15.3 times more 
sensitive in predicting new coronary events in older men 
and 4.3 times more sensitive in predicting new coronary 
events in older women than was electrocardiographic 
LVH (3).
At 10.2-year follow-up of 253 patients with hypertension, 
echocardiographic LVH increased the incidence of 
cardiovascular events 2.17 times, cardiovascular death 
28 times, and all-cause mortality 8 times (4). Patients with 
concentric LVH had the highest incidence of cardiovascular 
events and of mortality. Electrocardiographic LVH did 
not predict risk (4). At 37-month follow-up of 360 elderly 
patients with hypertension or coronary artery disease, 
echocardiographic LVH increased the incidence of new 
coronary events 2.0 times and of new stroke 2.8 times (6). 
Electrocardiographic LVH increased the incidence of new 
coronary events 1.4 times and of new stroke 1.7 times (6). 
Echocardiographic LVH was 4.3 times more sensitive in 
predicting new coronary events and 4.0 times more sensitive 
in predicting new stroke than was electrocardiographic 
LVH (6).
At 4-year follow-up of 3,220 persons aged 40 years and 
older in the Framingham Heart Study, echocardiographic 
LVH increased the r isk  of  cardiovascular  events 
1.49 times for men and 1.57 times for women per 
50 grams/meter increase in left ventricular mass/height, 
the risk of cardiovascular death 1.73 times for men and 
2.12 times for women per 50 grams/meter increase in left 
ventricular mass/height, and the risk of all-cause mortality 
1.49 times for men and 2.01 times for women per 50 grams/
meter increase in left ventricular mass/height (7). At 6- to 
7-year follow-up of 5,888 persons, mean age 73 years, in 
the Cardiovascular Health Study, compared to the lowest 
quartile of echocardiographic left ventricular mass, the 
highest quartile of echocardiographic left ventricular mass 
increased the incidence of coronary events 1.43 times, 
the incidence of stroke 1.52 times, and the incidence of 
congestive heart failure 3.36 times (8). Compared with 
normal left ventricular geometry, eccentric LVH increased 
the incidence of coronary events 2.05 times and for 
congestive heart failure 2.95 times. Compared with normal 
left ventricular geometry, concentric LVH increased the 
incidence of coronary events 1.61 times and for congestive 
heart failure 3.32 times (8).
At 42-month follow-up of 2,638 persons, mean age 
81 years, the incidence of new congestive heart failure 
was increased 2.73 times in persons with persistent 
electrocardiographic LVH compared with persons without 
electrocardiographic LVH (9). At 4.8-year follow-up 
of 922 patients with hypertension, patients with both 
echocardiographic LVH and electrocardiographic LVH had 
a 5.3 times higher incidence of hospitalization for congestive 
heart failure than patients without electrocardiographic 
or echocardiographic LVH (10). Patients with both 
echocardiographic LVH and electrocardiographic LVH had 
a 2.6 times higher incidence of hospitalization for congestive 
heart failure than patients without electrocardiographic 
LVH who had echocardiographic LVH (10).
At 10-year follow-up of 2,577 community-dwelling 
adults ,  mean age 72 years,  in the Cardiovascular 
Health study, addition of a 1-standard deviation higher 
echocardiographic left ventricular mass index to the 10-year 
risk prediction models containing traditional risk factors 
improved risk prediction for incident coronary heart disease 
25%, for incident coronary heart disease or heart failure 
or stroke 24%, and for incident congestive heart failure 
51% (11). The Multi-Ethnic Study of Atherosclerosis 
(MESA) Study performed cardiac magnetic resonance 
imaging for measurement of left ventricular mass and 
geometry to predict incident cardiovascular events in 5,098 
persons aged 45 to 84 years old (12). At 4-year follow-up, 
concentric LVH increased the incidence of coronary heart 
disease 2.1 times per gram/mL of left ventricular mass 
to volume ratio and the incidence of stroke 4.2 times per 
gram/mL of left ventricular mass to volume ratio (12). Left 
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ventricular mass alone increased the incidence of congestive 
heart failure 1.4 times per 10% increase in left ventricular 
mass (12). There are no data comparing the prognostic 
value of left ventricular mass and geometry obtained by 
magnetic resonance imaging versus by echocardiography.
At 2.71-year follow-up of 694 persons, mean age 
50 years, with hypertension, echocardiographic concentric 
left ventricular remodeling increased cardiovascular events 
2.56 times compared with echocardiographic normal 
left ventricular geometry (16). Echocardiograms were 
obtained in 9,771 patients older than 70 years with a normal 
left ventricular ejection fraction who were followed for 
3.1 years (17). All-cause mortality was 15.9% in patients 
with concentric LVH, 15.5% in patients with concentric left 
ventricular remodeling, 13.7% in patients with eccentric 
LVH, and 11.5% in patients with normal left ventricular 
geometry (17).
A prospective cohort sub-study of 941 patients aged 55 
to 80 years old in the Losartan Intervention for Endpoint 
Reduction in Hypertension (LIFE) trial with hypertension 
and electrocardiographic LVH had left ventricular mass 
measured by echocardiography (18). At 4.8-year follow-
up, reduction in echocardiographic left ventricular mass 
index by antihypertensive drug treatment reduced the 
incidence of cardiovascular mortality by 38%, stroke 
by 24%, myocardial infarction by 15%, and all-cause 
mortality by 28%, independent of systolic blood pressure 
and assigned treatment (18). At 4-year follow-up of 9,193 
persons aged 55 to 80 years old with hypertension and 
electrocardiographic LVH diagnosed by Cornell criteria 
or by Sokolow-Lyon voltage criteria in the LIFE trial, 
less severe electrocardiographic LVH by the Cornell 
criteria and by the Sokolow-Lyon voltage criteria were 
associated with a 14% and 17%, respectively, decrease in 
the composite endpoint of cardiovascular death, myocardial 
infarction, or stroke (19). At 4.7-year follow-up of 8,479 
persons, mean age 67 years old, with hypertension and 
electrocardiographic LVH diagnosed by the Cornell criteria, 
less severe electrocardiographic LVH was associated with 
a 19% reduction in heart failure hospitalization for every 
817-mm·msec lower Cornell product (20). In an outpatient 
clinic, at 67-month follow-up of patients with hypertension 
and echocardiographic LVH, regression of LVH occurred 
in 23% of patients treated with antihypertensive drugs (21).
A  m e t a - a n a l y s i s  w a s  p e r f o r m e d  o f  5  s t u d i e s 
inc luding 3 ,149 pat ients ,  mean age  range  48  to 
66 years old, with hypertension investigating the effect of 
regression of echocardiographic LVH on cardiovascular 
events (22). Follow-up ranged from 3 to 9 years. Regression 
of echocardiographic LVH was associated with a 46% 
reduction in cardiovascular events (22).
Loss of weight and reduction of sodium intake in 
patients with hypertension are effective in reducing 
echocardiographic LVH (23). Aggressive blood pressure 
control should be used to cause regression of LVH (21). 
A meta-analysis of 109 treatment studies including 2,357 
patents with hypertension showed that angiotensin-
converting enzyme inhibitors were the most effective 
antihypertensive drugs in reducing left ventricular mass (24). 
This analysis showed that angiotensin-converting enzyme 
inhibitors, beta blockers, and calcium channel blockers 
reduced left ventricular mass by reducing wall thickness, 
whereas diuretics reduced left ventricular mass by reducing 
left ventricular volume (24). Alpha-adrenergic blockers (25) 
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